Pharming Group Transitions Leadership for Future Growth
Today, Pharming Group N.V. announced significant developments following the Extraordinary General Meeting of Shareholders. This meeting resulted in the unanimous acceptance of all agenda proposals, paving the way for a new chapter in the company’s leadership.
New CEO Announcement
In a pivotal move, shareholders have formally appointed Mr. Fabrice Chouraqui as the new Executive Director and Chief Executive Officer of Pharming. This decision marks a shift in leadership, as Mr. Chouraqui takes the reins from former CEO Mr. Sijmen de Vries, who has guided the company through the last 16 years.
Leadership Transition
To ensure a seamless transition, Mr. de Vries will remain with Pharming as a strategic advisor until the end of 2025, offering his expertise and guidance during this critical period.
Remuneration Package Approved
The shareholders also approved key components of Mr. Chouraqui’s remuneration package. This decision highlights the board's confidence in his leadership potential as he takes the company forward.
Strategic Vision
Regarding the leadership change, Dr. Richard Peters, Chairman of the Board of Directors, expressed optimism for the future. He mentioned, "We are excited to welcome Fabrice as our new CEO. His experience and dedication will be pivotal in achieving Pharming’s objectives, especially in enhancing our market position within the rare disease domain. Moreover, we thank Sijmen for his remarkable contributions over the years.”
About Pharming Group N.V.
Pharming Group N.V. is not just another biopharmaceutical company; it’s a beacon of hope for patients suffering from rare and serious conditions. With a commitment to developing cutting-edge protein replacement therapies and precision medicines, Pharming is set to expand its impact across multiple markets. The company operates in more than 30 countries, ensuring that patients worldwide have access to life-changing treatments.
Global Presence and Commitment
Headquartered in Leiden, Pharming employs a dedicated team ensuring patient care remains at the forefront. Their portfolio not only includes innovative biopharmaceuticals but also a continuous dedication to research and development aimed at enhancing the quality of life for patients around the globe.
Company Outreach and Contact Information
For additional insights and updates, Pharming encourages stakeholders and interested parties to explore their website. The Investor Relations section provides comprehensive materials regarding the recent EGM, along with recordings and presentations. This effort demonstrates their transparency and commitment to investors.
For further public information, those interested can reach out to:
Pharming Group,
Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
Additionally, they have partnered with FTI Consulting and LifeSpring Life Sciences for broader communication efforts, ensuring that stakeholders are well-informed and engaged with their continued progress.
Frequently Asked Questions
What leadership changes occurred at Pharming Group?
Pharming Group has appointed Fabrice Chouraqui as their new CEO, succeeding Sijmen de Vries.
How long will Sijmen de Vries remain with Pharming?
He will stay on as a strategic advisor until the end of 2025 to facilitate a smooth transition.
What was approved at the Extraordinary General Meeting?
All agenda proposals, including the new CEO’s appointment and his remuneration package, were approved unanimously by shareholders.
What is Pharming’s focus in the biopharmaceutical industry?
Pharming is dedicated to developing therapies for rare diseases, emphasizing innovation and patient care.
How can I get more information about Pharming?
Visit their official website or connect through their Investor Relations for the latest updates and resources.
